AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Cantor Fitzgerald raised their FY2017 earnings estimates for shares of AxoGen in a note issued to investors on Tuesday. Cantor Fitzgerald analyst T. Steed now expects that the medical equipment provider will post earnings of ($0.28) per share for the year, up from their previous forecast of ($0.30). Cantor Fitzgerald currently has a “Overweight” rating and a $18.00 target price on the stock.
A number of other analysts have also recently weighed in on AXGN. BidaskClub cut shares of AxoGen from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Leerink Swann started coverage on shares of AxoGen in a research report on Monday, July 31st. They issued an “outperform” rating and a $22.00 price objective for the company. ValuEngine raised shares of AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Wedbush reissued an “outperform” rating and issued a $14.00 price objective (down from $17.00) on shares of AxoGen in a research report on Friday, May 19th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. AxoGen currently has a consensus rating of “Buy” and an average price target of $15.90.
Shares of AxoGen (NASDAQ:AXGN) opened at 15.10 on Thursday. The firm has a 50-day moving average price of $15.85 and a 200-day moving average price of $12.90. The firm’s market capitalization is $501.92 million. AxoGen has a 1-year low of $7.65 and a 1-year high of $17.25.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The company had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $14.40 million. During the same period last year, the firm earned ($0.09) earnings per share. AxoGen’s quarterly revenue was up 46.2% on a year-over-year basis.
A number of institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. boosted its position in AxoGen by 238.7% in the second quarter. Russell Investments Group Ltd. now owns 611,678 shares of the medical equipment provider’s stock worth $10,245,000 after buying an additional 431,057 shares during the last quarter. Lyon Street Capital LLC purchased a new position in AxoGen during the first quarter worth $2,166,000. Renaissance Technologies LLC purchased a new position in AxoGen during the first quarter worth $1,473,000. EAM Investors LLC boosted its position in AxoGen by 86.7% in the second quarter. EAM Investors LLC now owns 293,880 shares of the medical equipment provider’s stock worth $4,922,000 after buying an additional 136,453 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its position in AxoGen by 26.5% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 559,516 shares of the medical equipment provider’s stock worth $5,847,000 after buying an additional 117,178 shares during the last quarter. 64.58% of the stock is owned by institutional investors.
What are top analysts saying about AxoGen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AxoGen Inc. and related companies.